ASSENT 1Assessment of the Safety of a New Thrombolytic-1. A megatrial comparing the safety of different doses of TNK-tPA given as a single bolus to patients with acute myocardial infarction (MI).
Conclusion Death, nonfatal stroke, severe bleeding were low at all 3 doses, without significant differences between treatment groups. ASSENT 1 indicated that the rates of intracranial haemorrhage and mortality at 30 days for TNK-tPA were similar to that for tPA; while the 90-min coronary blood flow for TNK-tPA was similar to that for tPA, the 60 min results tended to favour TNK-tPA (55% TNK-tPA vs 48% for tPA).
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.